|[December 06, 2012]
MLL Munich Leukemia Laboratory Pairs RainDance ThunderStormTM System with Illumina MiSeq™ for Acute Myeloid Leukemia Sequencing
LEXINGTON, Mass. & MUNICH --(Business Wire)--
RainDance Technologies, Inc., the Digital Biology™ Company, and the MLL
Munich Leukemia Laboratory (MLL) today announced that MLL will be
releasing data for a new myeloid hematological malignancies gene panel
generated using RainDance Technologies' ThunderStorm™ System coupled
with Illumina's MiSeq™ platform. MLL will present initial results from a
technology evaluation and research study at the 54th Annual American
Society of Hematology (ASH) meeting next week in Atlanta.
MLL has developed a comprehensive, 31-gene deep-sequencing panel to
identify both favorable and adverse molecular markers for the
subclassification of Acute Myeloid Leukemia (AML) and Myelodysplastic
Syndromes (MDS). This panel uses RainDance's unique picodroplet
single-molecule PCR (News - Alert) enrichment solution and 2 x 250bp paired-end reads
generated on the Illumina MiSeq instrument. This panel also features
RainDance's DirectSeq™ tailed primer workflow, which incorporates
sequencing adapters in the primers and unique barcodes via a secondary
PCR, thereby eliminating sequencing library construction and enabling
4-5 samples to be analyzed per MiSeq run. To date, MLL has processed
more than 200 samples using the RainDance ThunderStorm System to
identify prognostically relevant mutations for AML and other myeloid
malignancies. MLL intends to use 2 x 250bp paired-end reads for this
panel later in its commercial operations.
"The number of molecular markers used to characterize myeloid
malignancies such as AML is constantly increasing. There is an acute
unmet need to test significantly larger gene panels while increasing
sensitivity and coverage by orders of magnitude," said Prof. Dr. Dr.
Torsten Haferlach, CEO of MLL. "By coupling the MiSeq platform with
RainDance's ThunderStorm System, we have developed the industry's
leading panel to analyze clinically relevant genes for AML and MDS using
high-throughput targeted sequencing. We have standardized onto the
RainDance-Illumina workflow to generate unparalleled data that can be
used to classify patients battling myeloid malignancies."
Data presented at the meeting will highlight a recent technology
evaluation and research study, where MLL analyzed 49 well-annotated
patients harboring myeloid malignancies. The targeted gene panel library
was constructed using RainDance's proprietary primer design pipeline and
sequenced using the Illumina MiSeq platform. The coverage per amplicon
was 2,095-fold, thus enabling highly sensitive detection of variants.
Total turn-around time from sample to result was less than fou days.
"MLL is one of several marquee research customers adopting our
ThunderStorm system and proven droplet-based PCR enrichment solution to
generate 100 percent genomic target coverage, completeness and
heterozygous concordance. Our system provides a highly simplified
workflow, high-throughput walkaway automation, and cost efficiencies in
sample prep, sequencing and informatics significantly better than any
other commercial solution," said Andy Watson, Chief Marketing Officer of
RainDance Technologies. "We are pleased to have MLL as our customer and
believe their AML/MDS panel will enable translational researchers to
better characterize life-threatening cancers."
Researchers from MLL will be discussing these and other data at the
annual meeting of the American Society of Hematology (ASH) in Atlanta,
December 8-11. These presentations include:
Saturday, December 8 at 7:30am and 2:00pm ET: Next
Generation Sequencing: Should it Become Part of Routine Diagnostics
for Leukemias and Other Myeloid Neoplasms In this talk, Prof. Dr.
Dr. Haferlach will discuss the application of deep sequencing and the
insights it has provided for both leukemias and other myeloid
neoplasms as well as the translation of recent discoveries into
state-of-the-art gene screening assays.
Monday, December 10 at 10:30am ET: Results of a
Comprehensive Next-Generation Sequencing Study Analyzing 32 Genes.
In this presentation, Dr. Wolfgang Kern (MLL) will discuss data from a
study of the molecular and cytogenetic characterization of MPAL-TM in
comparison of AML and T-ALL using a 32-gene screening panel.
Tuesday, December 11 at 7:30am ET: First Results of a
31-Gene Panel Targeted to Investigate Myeloid Malignancies by
Next-Generation Amplicon Deep-Sequencing. In this presentation,
Dr. Alexander Kohlmann (MLL) will discuss the use of RainDance's
sequence enrichment solution and Illumina's MiSeq instrument to
develop a novel 31-gene assay for myeloid malignancies.
For more information about the ASH meeting and these presentations,
please visit: www.hematology.org.
Dr. Kohlmann will also discuss data from the new myeloid malignancies
gene panel during a live RainDance-sponsored webinar, Thursday, December
13 at 11:00am ET. For more information and to register for this free
webinar, please visit: www.RainDanceTech.com/MLL-Webinar.
For more information about RainDance Technologies, please visit: www.RainDanceTech.com.
For more information about MLL, please visit: www.MLL.com.
About RainDance Technologies
RainDance Technologies, the Digital Biology™ Company, is pioneering the
use of high-throughput picodroplet-based analysis in human health and
life science research. The company's core RainStorm™ technology
generates millions of discrete droplets that can encapsulate a single
molecule, cell or reaction and be digitally analyzed and sorted one at a
time. The power, precision and simplicity of picodroplets enable
researchers to answer complex questions with unprecedented sensitivity
and quantitation. The complete RainDance solution includes automated
instrumentation, customizable bioinformatics and high-value consumables
and reagents for applications including targeted next-generation DNA
sequencing, methylation, digital PCR. Based in Lexington, Massachusetts,
the company supports scientists around the world through its
international sales and support operations and a global network of
distributors and service providers. For more information, please visit www.RainDanceTech.com.
For Research Use Only. Not for use in diagnostics procedures.
RainDance Technologies, the RainDance Technologies logo,
ThunderStorm, RainStorm, DirectSeq, and Digital Biology are trademarks
of RainDance Technologies, Inc. All other brands may be trademarks of
their respective holders.
[ Back To IBM News 's Homepage ]